Renal Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
The Meet-URO score combines inflammatory and clinical markers to predict response to nivolumab.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Stereotactic radiotherapy for oligoprogressive tumors while on oral systemic therapy delays time to treatment switch.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
A 14-mg starting dose of lenvatinib did not improve tolerability and had numerically worse efficacy than the approved 18-mg dose.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 2 trial, cabozantinib tolerably improved outcomes in patients pretreated with immunotherapy.